Rezolute, Inc.
NASDAQ:RZLTBiotechnology
Healthcare
$4.25 +6.16%
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
52W Low $1.07High $11.46
Volume 2.93M
Average 2.03M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$69.08M
FY 2025 · Annual
Investing Cash Flow
-$14.54M
FY 2025 · Annual
Financing Cash Flow
$107.33M
FY 2025 · Annual
+70.3% YoYCash Flow Statement
USD
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Depreciation & Amortization | 13K | 13K | 30K | 36K | 31K |
| Deferred Income Tax | (1.78M) | 0 | (1.37M) | 0 | 0 |
| Stock-Based Compensation | 3.97M | 3.69M | 7.27M | 7.36M | 7.12M |
| Change in Working Capital | (2.12M) | (642K) | 1.02M | 3.1M | 47K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 142K | (11K) | 2.14M | 1.08M | 1.42M |
| Other Working Capital | (2.26M) | (631K) | (1.12M) | 2.02M | (1.37M) |
| Other Non-Cash Items | 384K | (1.61M) | 352K | 595K | (1.86M) |
| Operating Cash Flow | (20.44M) | (39.62M) | (44.48M) | (57.37M) | (69.08M) |
| Capital Expenditures | 0 | 0 | (153K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 101.46M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (107.31M) | (66.4M) | (128.14M) |
| Sales of Investments | 0 | 0 | 6M | 115.1M | 113.6M |
| Other Investing Activities | 0 | 0 | (101.46M) | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (101.46M) | 48.7M | (14.54M) |
| Debt Repayment | 15M | (16.01M) | 0 | 0 | 0 |
| Common Stock Issued | 41M | 122.82M | 12.33M | 49.02M | 107.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.47M) | 31.39M | (759K) | 14.01M | 0 |
| Financing Cash Flow | 51.53M | 148.98M | 11.57M | 63.03M | 107.33M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.09M | 109.36M | (134.37M) | 54.36M | 23.71M |
| Free Cash Flow | (20.44M) | (39.62M) | (44.63M) | (57.37M) | (69.08M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$74.4M
+ D&A$31.0K
+ Stock-Based Comp$7.1M
+ Deferred Tax$0
+ Working Capital$47.0K
- Other Non-Cash-$1.9M
= Operating Cash Flow-$69.1M
- Capex$0
= Free Cash Flow-$69.1M
Analysis
FY2025 free cash flow is -$69.1M. FCF conversion is 92.8% of net income. Operating cash flow was -$69.1M, with capex of $0. The largest bridge item is Stock-Based Comp at $7.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| FWP | FWP filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 424B5 | 424B5 filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 |
Does RZLT generate free cash flow?
Rezolute, Inc. (RZLT) generated -$69.08M of free cash flow in fiscal 2025.
How much operating cash flow does RZLT produce?
Operating cash flow was -$69.08M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.